Journals in Pharmacology general

1-10 of 30 results in All results

Antiviral Research

• ISSN: 0166-3542
• 5 Year impact factor: 5
• Impact factor: 4.5

Antiviral Research aims to publish manuscripts in the field of prevention and treatment of viral diseases in humans and vertebrate animals, and encourages authors to the submit manuscripts describing the activity of well-defined chemical compounds for the treatment of viral diseases. The journal is an Official Publication of the International Society for Antiviral Research. The types of papers published in Antiviral Research includes original research reports, short communications, commentaries and invited review* articles on the control of viral infections in humans. The journal’s scope encompasses:antiviral drugs, antibodies and host-response modifiers, including their synthesis, in vitro and in vivo testing and mechanisms of action.identification and validation of new drug targets;laboratory animal models of viral diseases for antiviral efficacy testing;evolution of drug-resistant viruses and the development of effective counter measures;pathogenesis of viral diseases and mechanisms of viral evasion of host immune responses;assessments of drug safety;new or improved vaccines against viral infections of humans; the prevention and treatment of viral diseases of vertebrate animals, and reports of the testing of veterinary vaccines in the target animal species. All papers must include a sufficiently detailed description of methods to permit other investigators to replicate the experiments. Authors reporting the antiviral effect of a novel small-molecule drug must reveal its chemical structure. Claims of in vitro or in vivo efficacy of a drug or vaccine must be supported by appropriate statistical analysis that must be clearly described in the manuscript.Antiviral Research journal does not publish reports on viral diseases of plants or of insects, crustaceans or other invertebrates. Studies of viral diseases of livestock and companion animals must be clearly related to the development of realistic therapies. Papers on veterinary vaccines should report findings in the target animal species.We discourage the submission of manuscripts reporting the antiviral activity of unpurified natural products, or of partially purified substances of natural origin for which a mechanism of action has not been determined. Manuscripts claiming an antiviral effect of homeopathic products or other highly diluted preparations, or which fail to clearly identify the biological ingredient or molecule responsible for the antiviral activity of an experimental therapy, will not be considered for publication. Articles describing antiseptics with broad-spectrum antimicrobial activity will not be accepted. We discourage the submission of in silico docking studies or other computer-based predictions of antiviral activity that are not supported by data from biological assays. Citations of reports that have not undergone peer review must include the note "[not peer-reviewed]."ISAR members Authors who are ISAR members are encouraged to contact ISAR after their paper has been accepted for publication in order to benefit from their published work being highlighted in ISAR postings on their social media platforms (further details on this will be given in the AVR acceptance letter). *Antiviral Research journal has started a new initiative to publish at least two thematic special issues per year, containing invited reviews in addition to the ad hoc invitations to experts in the areas within the scope of the journal.

Subscribe

Biochemical Pharmacology

• ISSN: 0006-2952
• 5 Year impact factor: 5.2
• Impact factor: 5.3

Biochemical Pharmacology publishes original research findings and review articles related to the elucidation of cellular and tissue function(s) at the biochemical and molecular levels, the modification of cellular phenotype(s) by genetic, transcriptional/translational or drug/compound-induced modifications, as well as the pharmacodynamics and pharmacokinetics of xenobiotics and drugs, the latter including both small molecules and biologics.The journal's target audience includes scientists engaged in the identification and study of the mechanisms of action of xenobiotics, biologics and drugs and in the drug discovery and development process.All areas of cellular biology and cellular, tissue/organ and whole animal pharmacology fall within the scope of the journal. Drug classes covered include anti-infectives, anti-inflammatory agents, chemotherapeutics, cardiovascular, endocrinological, immunological, metabolic, neurological and psychiatric drugs, as well as research on drug metabolism and kinetics. While medicinal chemistry is a topic of complementary interest, manuscripts in this area must contain sufficient biological data to characterize pharmacologically the compounds reported. Submissions describing work focused predominately on chemical synthesis and molecular modeling will not be considered for review.While particular emphasis is placed on reporting the results of molecular and biochemical studies, research involving the use of tissue and animal models of human pathophysiology and toxicology is of interest to the extent that it helps define drug mechanisms of action, safety and efficacy.Reports describing experiments conducted with natural product mixtures, plant or animal extracts will not be considered for publication unless the structures and concentrations of all component substances are known, and the agents can be easily obtained by others wishing to replicate the study.The chemical structure of all novel compounds tested must be included in the submitted manuscript or be readily accessible in the published literature. References to structures in the patent literature must unambiguously identify a single molecular structure. All compounds, reagents, instrumentation and equipment employed in a study must be available from identified commercial suppliers, bio/pharmaceutical companies or from individuals holding legal rights to their use. Submissions will not be considered for publication if the chemical structures of tested compounds are not revealed, generally known, or accessible in the literature.Original research submissions must contain:A rationale for the selection of the compound/drug for study as well as for the concentrations/doses employed. Quantities used for concentration- and dose-response experiments should vary logarithmically, e.g., 1, 3, 10, 30 mg/kg, 0.1, 1.0, 10, 100 nanomolar, etc. Justification must be provided for studying only a single concentration or dose of a compound, especially as it relates to reference standards and antagonists/modulators of receptors, enzymes and signaling pathways.Justification must also be provided for the selection of the statistical tests employed as they relate to the experimental design.It is expected that all findings have been subjected to rigorous quantitative analyses, with the calculation and reporting of IC50, Ki, EC50, etc., values. These must be derived from a minimum of three (3) separate and distinct experiments, with the replicates within any single experiment being averaged to obtain a single value for that experimental series.Manuscripts that fail to meet these criteria will be subject to rejection without peer-review.US National Institutes of Health (NIH) voluntary posting ("Public Access") policy:Biochemical Pharmacology and Elsevier facilitate the author's response to the NIH Public Access Policy.

Subscribe

Cellular Signalling

• ISSN: 0898-6568
• 5 Year impact factor: 4.4
• Impact factor: 4.4

Cellular Signalling publishes original research describing fundamental and clinical findings on the mechanisms, actions and structural components of cellular signalling systems in vitro and in vivo.Cellular Signalling aims at full length research papers defining signalling systems ranging from microorganisms to cells, tissues and higher organisms.Cellular Signalling strives to offer a fair and fast peer-review process with a single round of revisions. Reviews are by invitation-only. Short Reports are not accepted.

Subscribe

Comparative Biochemistry and Physiology - Part C: Toxicology & Pharmacology

• ISSN: 1532-0456
• 5 Year impact factor: 3.9
• Impact factor: 3.9

Comparative Biochemistry & Physiology (CBP) publishes papers in comparative, environmental and evolutionary physiology.Part C: Toxicology and Pharmacology (CBPC), focuses on toxicological mechanisms at different levels of organization, primarily chemical and drug action, biotransformation of xenobiotics, endocrine disruptors, nanoparticles, pharmaceuticals, and natural products chemistry. Most studies employ a molecular approach in combination with observations of higher levels of organization to assess the mechanism by which xenobiotics affect physiology. Analytical verification of exposure concentrations is strongly recommended for manuscripts reporting toxicological studies.All four CBP journals support and follow the editorial direction from all the major societies in the field:Australia & New Zealand Society of Comparative Physiology and Biochemistry (ANZSCPB)American Physiological Society (APS)Canadian Society of Zoologists (CSZ)Deutsche Zoologische Gesellschaft (DZG)European Society of Comparative Physiology and Biochemistry (ESCPB)Japanese Society for Comparative Physiology and Biochemistry (JSCPB)South American Society for Comparative Physiology and Biochemistry (SASCPB)Societe de Physiologie (SDP)Society for Experimental Biology (SEB)Society for Integrative & Comparative Biology (SICB)Benefits to authorsCBP journals are focused on promoting the authors and the work published in the journal:All articles are carefully evaluated directly by the Editors-in-Chief who are leading experts in their field.Availability: contact the Editor-in-Chief for any questions you may have.The Journal will provide upon request free PDFs to all authors who may not have access to their articles via their institution or library.Publication is free to authors (no color or page charges).Supporting open access: if your funding body or institution requires your article to be open access, CBP offers that option. Please see details here.Reuse figures from any CBP article via "get rights and content" hyperlink available within each article (below author names and affiliations) on ScienceDirect.Please click here for more information on more general author services.Other CBP journals Part A (CBPA): Molecular & Integrative Physiology Part B (CBPB): Biochemistry & Molecular Biology Part D (CBPD): Genomics & Proteomics

Subscribe

Contemporary Clinical Trials

• ISSN: 1551-7144
• 5 Year impact factor: 2.1
• Impact factor: 2

Contemporary Clinical Trials is an international peer reviewed journal that publishes manuscripts pertaining to all aspects of clinical trials, including, but not limited to, design, conduct, analysis, regulation and ethics. Manuscripts submitted should appeal to a readership drawn from disciplines including medicine, biostatistics, epidemiology, computer science, management science, behavioural science, pharmaceutical science, and bioethics. Full-length papers not exceeding 4,000 words, short communications not exceeding 1,500 words, as well as systemic reviews of clinical trials and methodologies will be published. Perspectives/commentaries on current issues and the impact of clinical trials on the practice of medicine and health policy are also welcome.The following topics are covered in the journal:Unconventional design features of specific trials and their rationalePreliminary or full results of clinical trials with unconventional design featuresStatistical methods for all aspects of clinical trialsMethodologies for clinical trial operations including trial management and optimization; patient recruitment and retention; and trial quality monitoring and assessmentData management methodologies including data collection; database maintenance; data quality assurance; safety monitoring and risk management; and patient registriesRegulatory requirements and their impact on clinical trialsEthical and legal considerations in clinical trialsRisk-benefit, cost-effectiveness and decision analyses in clinical trialsContemporary Clinical Trials is unique in that it is outside the confines of disease specifications, and it strives to adapt and grow with an expanding clinical trials landscape as the needs of clinical research evolve in today's dynamic healthcare environment.Having taken upon the important role as a platform for knowledge exchange between experts in different disciplines related to clinical trials, the ultimate goal of Contemporary Clinical Trials is to advance this field of research for the benefit of patients.We look forward to receiving your contribution! Authors are also welcome to submit to the journal's open access companion title, Contemporary Clinical Trials Communications .Benefits to authors Contemporary Clinical Trials also provides many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Subscribe

Current Opinion in Pharmacology

• ISSN: 1471-4892
• 5 Year impact factor: 4.1
• Impact factor: 4

Current Opinion in Pharmacology (COPHAR) publishes authoritative, comprehensive, and systematic reviews. COPHAR helps specialists keep up to date with a clear and readable synthesis on current advances in pharmacology and drug discovery. Expert authors annotate the most interesting papers from the expanding volume of information published today, saving valuable time and giving the reader insight on areas of importance.COPHAR is part of the Current Opinion and Research (CO+RE) suite of journals and is a companion to the new primary research, open access journal, Current Research in Pharmacology and Drug Discovery (CRPHAR) .COPHAR divides the subject of pharmacology into themed sections, each of which is reviewed once a year. The amount of space devoted to each section is related to its importance. Themes include neurosciences; cardiovascular and renal; respiratory; musculoskeletal; cancer; immunomodulation; anti-infectives; new technologies; gastrointestinal; endocrine; and metabolic diseases.The journal builds on Elsevier's reputation for excellence in scientific publishing and long-standing commitment to communicating reproducible biomedical research targeted at improving human health.Expertise - Expert authors, who are leaders in their field, are invited to write short review articles in which they present recent developments in their subject and provide short annotations to the papers that they think are most relevant.Comprehensiveness - There are 27 high-impact Current Opinion review journals in a range of subjects from food science to green and sustainable chemistry.Impact - In addition to a vast readership, Current Opinion titles enjoy high citations, Impact Factors, and CiteScores.Selection of topics to be reviewed Section Editors, who are major authorities in the field, are appointed by the Editors of the journal. They divide their section into a number of topics, ensuring that the field is comprehensively covered and that all issues of current importance are emphasised. Section Editors commission reviews from authorities on each topic that they have selected.Reviews Authors write short review articles in which they present recent developments in their subject, emphasising the aspects that, in their opinion, are most important. In addition, they provide short annotations to the papers that they consider to be most interesting from all those published in their topic over the previous year.Editorial Overview Section Editors write a short overview at the beginning of the section to introduce the reviews and to draw the reader's attention to any particularly interesting developments.Ethics in Publishing: General StatementThe Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.For more information, please refer to: https://www.elsevier.com/conflictsofinterest

Subscribe

Currents in Pharmacy Teaching and Learning

• ISSN: 1877-1297
• 5 Year impact factor: 1.7
• Impact factor: 1.3

Currents in Pharmacy Teaching and Learning is devoted to dissemination of high quality, peer-reviewed scholarship relevant to all areas of pharmacy education—promoting educational research excellence. The Journal maintains a particular focus in two major areas: pharmacy faculty development in the scholarship of teaching and learning and the scholarship of interprofessional pharmacy education. With diverse editorial board members, authors, and peer reviewers, the Journal engages a variety of stakeholders in pharmacy education: educators, researchers, faculty practitioners, as well as interprofessional colleagues. Diverse author contributions are within original research, review articles, commentaries, and letters categories.Original research topics include, but are not limited to:Scholarship of Teaching and Learning: teaching/learning strategies; interprofessional educationQuality Improvement - assessment of programmatic/curricular outcomesCurricular Revision – design, implementation, evaluationNew school/program strategiesAttitudes/perceptions within pharmacy education

Subscribe

Environmental Toxicology and Pharmacology

• ISSN: 1382-6689
• 5 Year impact factor: 4.4
• Impact factor: 4.2

Environmental Toxicology and Pharmacology publishes the results of studies concerning toxic and pharmacological effects of (human and veterinary) drugs and of environmental contaminants in animals and man.Areas of special interest are: molecular mechanisms of toxicity, biotransformation and toxicokinetics (including toxicokinetic modelling), molecular, biochemical and physiological mechanisms explaining differences in sensitivity between species and individuals, the characterisation of pathophysiological models and mechanisms involved in the development of effects and the identification of biological markers that can be used to study exposure and effects in man and animals.In addition to full length papers, short communications, full-length reviews and mini-reviews, Environmental Toxicology and Pharmacology will publish in depth assessments of special problem areas. The latter publications may exceed the length of a full length paper three to fourfold. A basic requirement is that the assessments are made under the auspices of international groups of leading experts in the fields concerned. The information examined may either consist of data that were already published, or of new data that were obtained within the framework of collaborative research programmes. Provision is also made for the acceptance of minireviews on (classes of) compounds, toxicities or mechanisms, debating recent advances in rapidly developing fields that fall within the scope of the journal.Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Subscribe

European Journal of Pharmaceutics and Biopharmaceutics

• ISSN: 0939-6411
• 5 Year impact factor: 4.8
• Impact factor: 4.4

Official Journal of the International Association for Pharmaceutical TechnologyThe European Journal of Pharmaceutics and Biopharmaceutics provides a medium for the publication of novel, innovative and hypothesis-driven research from the areas of Pharmaceutics and Biopharmaceutics.Topics covered include for example:Design and development of drug delivery systems for pharmaceuticals and biopharmaceuticals (small molecules, proteins, nucleic acids)Aspects of manufacturing process designBiomedical aspects of drug product designStrategies and formulations for controlled drug transport across biological barriersPhysicochemical aspects of drug product developmentNovel excipients for drug product designDrug delivery and controlled release systems for systemic and local applicationsNanomaterials for therapeutic and diagnostic purposesAdvanced therapy medicinal productsMedical devices supporting a distinct pharmacological effect"The Rules of 3"The Editors and Editorial board have developed the "Rules of 3". Authors must consider the following three criteria before they submit a manuscript and set the whole process of editing and reviewing at work: 1. The paper must report on novel findings that are not merely an unprecedented combination of known aspects in pharmaceutics and biopharmaceutics of major importance. 2. A paper must be based on a thorough and extensive study, using established or well-described methods and including proper controls. Research must be hypothesis-driven and conclusions must be supported by the data presented. 3. The study described in the manuscript must not merely confirm the state of the art in the field of pharmaceutics and biopharmaceutics, but advance it.

Subscribe

European Journal of Pharmacology

• ISSN: 0014-2999
• 5 Year impact factor: 4.3
• Impact factor: 4.2

The European Journal of Pharmacology publishes research papers covering all aspects of experimental pharmacology with focus on the mechanism of action of structurally identified compounds affecting biological systems.The scope includes: Behavioural pharmacology, Neuropharmacology and psychopharmacology, Cardiovascular pharmacology, Pulmonary, gastrointestinal and urogenital pharmacology, Endocrine pharmacology, Immunopharmacology and inflammation, Molecular and cellular pharmacology, Regenerative pharmacology, Biologicals and biotherapeutics, Translational pharmacology and Nutriceutical pharmacology.The journal publishes full-length papers and reviews. Ethnopharmacological studies with plant extracts or mixtures are not in scope of this journal.The table of contents for this journal is now available pre-publication, via e-mail, as part of the free ContentsDirect service from Elsevier. Please send an e-mail message to [email protected] for further information about this service.Benefits to authors We also provide many author benefits, such as free PDFs, a liberal copyright policy, special discounts on Elsevier publications and much more. Please click here for more information on our author services .Please see our Guide for Authors for information on article submission. If you require any further information or help, please visit our Support Center

Subscribe